Biotecnología microbiana y salud

Keyphrases

1. Breast Cancer 100%
2. Tumor-infiltrating Lymphocytes 64%
3. Peruvian 61%
4. Peru 41%
5. Triple-negative Breast Cancer 36%
6. Protease 36%
7. Bovine Chromaffin Cells 32%
8. Nicotine 29%
9. Nicotinic Receptors 27%
10. Oncology Biomarkers 25%
11. Immuno-oncology 25%
12. Erythrina Edulis 24%
13. Response Surface Methodology 24%
14. Extremophilic 24%
15. Hydrolyzate 22%
16. Alcalase 22%
17. Tumor 22%
18. Breast Cancer Patients 20%
19. Hydrolysis 20%
20. Indigenous Americans 19%
21. Overall Survival 19%
22. PIK3CA mutation 18%
23. Antioxidant Peptides 18%
24. Stromal Tumor-infiltrating Lymphocytes 18%
25. Seed Storage Proteins 18%
26. Lupinus mutabilis 18%
27. Breast Cancer Subtypes 18%
28. Residual Disease 17%
29. Glioblastoma 17%
30. Human Epidermal Growth Factor Receptor 2 (HER2) 16%
31. Catecholamine Secretion 16%
32. Tumor-infiltrating Immune Cells 16%
33. Avibacterium Paragallinarum 16%
34. Process Conditions 16%
35. Capsicum Annuum 16%
36. Fermentation Process Optimization 16%
37. Chili Pepper 16%
38. Phase II Trial 16%
39. Distillers Dried Grains with Solubles 16%
40. Pseudomonas Aeruginosa (P. aeruginosa) 16%
41. Chenopodium Pallidicaule 16%
42. Chromaffin Cells 16%
43. Oxidative Stress 16%
44. Molecular Characterization 15%
45. Inward Current 14%
46. Albumin 14%
47. Antioxidant 13%
48. Pepper Fruits 13%
49. ATP Secretion 12%
50. Functional Peptides 12%
51. Clinical Features 12%
52. Estrogen Receptor-positive 12%
53. Malignancy 11%
54. Triple Negative 11%
55. Early Breast Cancer 11%
56. Pathologist 11%
57. Clinical Trials 10%
58. Acidification Rate 10%
59. Metabolic Alterations 10%
60. Programmed Death-ligand 1 (PD-L1) 10%
61. Odds Ratio 10%
62. Protein Concentrate 10%
63. Radiotherapy 10%
64. Serine Protease 10%
65. Neoadjuvant 10%
66. Microorganisms 10%
67. Ornithobacterium Rhinotracheale 10%
68. Cancer Control 10%
69. Hydrolysate 10%
70. Degree of Hydrolysis 10%
71. Neoadjuvant Therapy 9%
72. Fast Component 9%
73. Slow Component 9%
74. Depolarization 9%
75. Alzheimer's Disease 9%
76. Soluble Protein 9%
77. Salterns 9%
78. Confidence Interval 9%
79. Proteolytic Activity 9%
80. Risk Management 9%
81. Prognostic Factors 9%
82. Neoadjuvant Chemotherapy 9%
83. 16S rRNA Gene 8%
84. Anthracyclines 8%
85. Lymphocyte Level 8%
86. Polymorphism 8%
87. Chronic Disease 8%
88. Functional Food 8%
89. Nutraceuticals 8%
90. MINDACT 8%
91. Genomic Risk 8%
92. CD163 8%
93. EORTC 8%
94. Docetaxel 8%
95. Saline Environment 8%
96. Enterobacter 8%
97. Genetic Epidemiology 8%
98. Tarwi 8%
99. Recombinant 8%
100. Extracellular Calcium 8%